New weight-loss drugs have grown in popularity in recent years due to increased availability and the introduction of tablets.

Several studies suggest GLP-1 drugs may lower cancer risk. But that benefit may be due to the patients themselves: those who are healthier, wealthier and with better access to care.

GoodRx reports that Medicare's new GLP-1 Bridge program allows eligible Part D enrollees to access weight-loss medications for a $50 copay, starting July 1, 2026.

Fatty15 reports metabolic health is more important than weight loss, focusing on factors like blood sugar and cholesterol, not just body weight.

GoodRx reports that Rybelsus is being phased out in favor of the Ozempic pill, which contains the same active ingredient but requires a different dosage. 

GLP-1 injections, which are used for weight loss, cost around $500 a month.

GLP-1 medications are drugs that mimic a natural hormone in the body called glucagon-like peptide-1, which helps regulate appetite.

Doctronic reports that Foundayo, an oral GLP-1 for diabetes, shows promise but lacks long-term safety data beyond 68 weeks; ongoing studies are needed.

GoodRx reports Wegovy HD is a higher-dose version of Wegovy, offering potentially greater weight loss but with increased side effects.

GoodRx reports that Foundayo, a new oral weight-loss pill, is FDA-approved for obesity treatment, offering an alternative to injections with effective results.